Revolution Medicines, Inc. reiterated full year 2022 GAAP net loss to be between $260 million and $290 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.96 USD | +1.78% | +2.98% | +25.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.38% | 5.82B | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022